Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease A Systematic Review and Meta-analysis

被引:640
作者
Palmer, Suetonia C. [2 ,3 ]
Hayen, Andrew [4 ]
Macaskill, Petra [4 ]
Pellegrini, Fabio [1 ,5 ]
Craig, Jonathan C. [4 ,6 ]
Elder, Grahame J. [7 ,8 ]
Strippoli, Giovanni F. M. [1 ,4 ,6 ,9 ]
机构
[1] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, I-66030 Santa Maria Imbaro, Italy
[2] Univ Otago, Dept Med, Christchurch, New Zealand
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[4] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
[5] Sci Inst Casa Sollievo della Sofferenza, Foggia, Italy
[6] Cochrane Renal Grp, Sydney, NSW, Australia
[7] Westmead Hosp, Dept Renal Med, Sydney, NSW, Australia
[8] Garvan Inst Med Res, Bone & Mineral Program, Sydney, NSW, Australia
[9] Diaverum, Med Sci Off, Lund, Sweden
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 305卷 / 11期
关键词
MINERAL-BONE DISORDER; HEMODIALYSIS-PATIENTS; MORTALITY RISK; DIALYSIS PATIENTS; VITAMIN-D; PRACTICE PATTERNS; RETROSPECTIVE COHORT; PERITONEAL-DIALYSIS; PHOSPHATE PRODUCT; PATIENT SURVIVAL;
D O I
10.1001/jama.2011.308
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Context Clinical practice guidelines on the management of mineral and bone disorders due to chronic kidney disease recommend specific treatment target levels for serum phosphorus, parathyroid hormone, and calcium. Objective To assess the quality of evidence for the association between levels of serum phosphorus, parathyroid hormone, and calcium and risks of death, cardiovascular mortality, and nonfatal cardiovascular events in individuals with chronic kidney disease. Data Sources The databases of MEDLINE (1948 to December 2010) and EMBASE (1947 to December 2010) were searched without language restriction. Hand searches also were conducted of the reference lists of primary studies, review articles, and clinical guidelines along with full-text review of any citation that appeared relevant. Study Selection Of 8380 citations identified in the original search, 47 cohort studies (N=327 644 patients) met the inclusion criteria. Data Extraction The characteristics of study design, participants, exposures, and covariates together with the outcomes of all-cause mortality, cardiovascular mortality, and nonfatal cardiovascular events at different levels of serum phosphorus, parathyroid hormone, and calcium were analyzed within studies. Data were summarized across studies (when possible) using random-effects meta-regression. Data Synthesis The risk of death increased 18% for every 1-mg/dL increase in serum phosphorus (relative risk [RR], 1.18 [95% confidence interval {CI}, 1.12-1.25]). There was no significant association between all-cause mortality and serum level of parathyroid hormone (RR per 100-pg/mL increase, 1.01 [95% CI, 1.00-1.02]) or serum level of calcium (RR per 1-mg/dL increase, 1.08 [95% CI, 1.00-1.16]). Data for the association between serum level of phosphorus, parathyroid hormone, and calcium and cardiovascular death were each available in only 1 adequately adjusted cohort study. Lack of adjustment for confounding variables was not a major limitation of the available studies. Conclusions The evidentiary basis for a strong, consistent, and independent association between serum levels of calcium and parathyroid hormone and the risk of death and cardiovascular events in chronic kidney disease is poor. There appears to be an association between higher serum levels of phosphorus and mortality in this population. JAMA. 2011;305(11):1119-1127 www.jama.com
引用
收藏
页码:1119 / 1127
页数:9
相关论文
共 79 条
[1]
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[2]
[Anonymous], GUID AN CHRON KIDN D
[3]
[Anonymous], NEPHROL DIAL TRAN S2
[4]
Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters [J].
Avram, MM ;
Sreedhara, R ;
Fein, P ;
Oo, KK ;
Chattopadhyay, J ;
Mittman, N .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (01) :S77-S80
[5]
METAANALYSIS OF EPIDEMIOLOGIC DOSE-RESPONSE DATA [J].
BERLIN, JA ;
LONGNECKER, MP ;
GREENLAND, S .
EPIDEMIOLOGY, 1993, 4 (03) :218-228
[6]
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[7]
TRENDS AND CONSEQUENCES OF MINERAL BONE DISORDER IN HAEMODIALYSIS PATIENTS: LESSONS FROM THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS) [J].
Blayney, Margaret J. ;
Tentori, Francesca .
JOURNAL OF RENAL CARE, 2009, 35 :7-13
[8]
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[9]
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[10]
A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology [J].
Block, Geoffrey A. ;
Persky, Martha S. ;
Ketteler, Markus ;
Kestenbaum, Bryan ;
Thadhani, Ravi ;
Kooienga, Laura ;
Spiegel, David ;
Asplin, John ;
Ehrlich, James ;
Dennis, Vincent ;
Nissenson, Allen ;
Chertow, Glenn M. ;
Wheeler, David C. .
HEMODIALYSIS INTERNATIONAL, 2009, 13 (03) :360-362